- Featured Product
- KD/KO Validated
ELK1 Polyclonal antibody
ELK1 Polyclonal Antibody for ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human
Applications
WB, ELISA
Conjugate
Unconjugated
Cat no : 14507-1-AP
Synonyms
Validation Data Gallery
Published Applications
KD/KO | See 1 publications below |
WB | See 3 publications below |
Product Information
14507-1-AP targets ELK1 in WB, ELISA applications and shows reactivity with human samples.
Tested Reactivity | human |
Cited Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | ELK1 fusion protein Ag5966 |
Full Name | ELK1, member of ETS oncogene family |
Calculated Molecular Weight | 45 kDa |
GenBank Accession Number | BC056150 |
Gene Symbol | ELK1 |
Gene ID (NCBI) | 2002 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
E twenty-six (ETS)-like transcription factor 1, also known as ELK1, is a member of the Ets family of transcription factors and of the ternary complex factor (TCF) subfamily. It is targeted in the nucleus by three major MAP kinase pathways as well as the CaMKII pathway. phosphorylation of nuclear Elk1 enhances its ability to bind DNA at serum response elements and stimulate transcription of immediate early genes. Elk1 plays important roles in various contexts, including long-term memory formation, drug addiction, Alzheimer's disease, down syndrome, breast cancer, and depression. This antibody got an 62 kd band in western blotting maybe duo to its phosphorylation
Publications
Species | Application | Title |
---|---|---|
Br J Pharmacol L-Hcy-induced cathepsin V mediates the vascular endothelial inflammation in hyperhomocysteinemia. | ||
Oncol Lett MicroRNA-326 suppresses the proliferation, migration and invasion of cervical cancer cells by targeting ELK1. |